12.11.12
PerkinElmer, Inc. has launched a new range of assay kits using AlphaLISA technology to help improve the safety testing, manufacturing and quality control of biotherapeutic drugs. PerkinElmer developed the new assays to help meet the stringent performance requirements relating to drug impurities and toxic effects.
According to the company, the AlphaLISA technology helps to achieve higher quality results than the comparable ELISA (enzyme-linked immunosorbent assay) technology in half the time, and has a simple protocol with fewer assay steps, resulting in better inter- and intra-assay precision, improved coefficient of variations (CVs), and easier method transfer to downstream departments.
“PerkinElmer is continuously seeking new ways to improve human health through the development of innovative technologies,” said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. “Adverse reactions due to drug toxicity comprise a real issue that we are passionate about helping to minimize. We are very excited to enable our customers to improve the safety and efficacy of new biotherapeutic drugs being developed through our new assay kits which are the latest addition to our growing biotherapeutics portfolio.”
According to the company, the AlphaLISA technology helps to achieve higher quality results than the comparable ELISA (enzyme-linked immunosorbent assay) technology in half the time, and has a simple protocol with fewer assay steps, resulting in better inter- and intra-assay precision, improved coefficient of variations (CVs), and easier method transfer to downstream departments.
“PerkinElmer is continuously seeking new ways to improve human health through the development of innovative technologies,” said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. “Adverse reactions due to drug toxicity comprise a real issue that we are passionate about helping to minimize. We are very excited to enable our customers to improve the safety and efficacy of new biotherapeutic drugs being developed through our new assay kits which are the latest addition to our growing biotherapeutics portfolio.”